Citation: Rr. Freedman et al., Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma, J RHEUMATOL, 28(1), 2001, pp. 119-121
Citation: Rr. Freedman et R. Girgis, Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness, HYPERTENSIO, 35(3), 2000, pp. 795-799
Authors:
Badesch, DB
Tapson, VF
McGoon, MD
Brundage, BH
Rubin, LJ
Wigley, FM
Rich, S
Barst, RJ
Barrett, PS
Kral, KM
Jobsis, MM
Loyd, JE
Murali, S
Frost, A
Girgis, R
Bourge, RC
Ralph, DD
Elliott, CG
Hill, NS
Langleben, D
Schilz, RJ
McLaughlin, VV
Robbins, IM
Groves, BM
Shapiro, S
Medsger, TA
Gaine, SP
Horn, E
Decker, JC
Knobil, K
Citation: Db. Badesch et al., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease - A randomized, controlled trial, ANN INT MED, 132(6), 2000, pp. 425
Citation: Rr. Freedman et al., Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma, J RHEUMATOL, 26(11), 1999, pp. 2386-2388
Authors:
Tirdel, GB
Girgis, R
Fishman, RS
Theodore, J
Citation: Gb. Tirdel et al., Metabolic myopathy as a cause of the exercise limitation in lung transplant recipients, J HEART LUN, 17(12), 1998, pp. 1231-1237